IMPLANTATION WITH MEDTECH COCHLEAR IMPLANT SYSTEM IN ADULTS

HCL TECHNOLOGIES LIMITED0 个研究点目标入组 0 人开始时间: 待定最近更新: 2022年10月17日

试验速览

暂无简介。

•1.18 years of age or older
•2.Severe-to-profound, sensorineural hearing loss ( >70 dB), determined by pure tune at 500Hz, 1000Hz and 2000Hz
•3.bilateral or Postlingual onset of severe or profound hearing loss
•4.Limited benefit from appropriate binaural hearing aids (verified by standard clinical practice), as defined by aided test scores of 50% correct or less in the ear to be implanted (60% or less in the best-aided listening condition) on tests of open set sentence recognition.
•I. Consistent with the Minimum Speech Test Battery (2011), it is required that all subjects be evaluated
•5.Moderate to profound hearing loss in the low frequencies and profound (Ã¢â?°Â¥ 90 dB HL) hearing loss in the mid to high speech frequencies
•6.eBERA Ã¢â?¬â?? Electrical brainstem evoked response audiometry to ensure benefit from the Implant. eBERA can be performed during surgery itself.

•1.Sensorineural severe-to-profound hearing loss greater than 20 years at Ã¢â?°Â¥ 2 kHz and above
•2.Simultaneous bilateral cochlear implantation or prior cochlear implantation in the ear to be implanted
•3.Medical or psychological conditions that contraindicate undergoing general anaesthesia or surgery
•4.Ossification, malformation or any other cochlear anomaly, such as common cavity, that might prevent complete insertion of the electrode array, as confirmed by medical examination
•5.Hearing impairment due to lesion or neuropathy of the acoustic nerve, VIII nerve or central auditory pathway (audio Neuropathy Spectrum disorder).
•6.Active middle-ear infection
•7.Tympanic membrane perforation
•8.Unwillingness or inability of the candidate to comply with all investigational requirements as determined by the Investigator
•9.Patients with existing CSF shunts or drains, existing perilymph fistula, skull fracture or CSF leak
•10.Patients with recurrent episodes of bacterial meningitis
•11.Any other Cochlear Implant

发起方

HCL TECHNOLOGIES LIMITED